ES2172535T3 - Antagonistas de los receptores de la endotelina. - Google Patents

Antagonistas de los receptores de la endotelina.

Info

Publication number
ES2172535T3
ES2172535T3 ES94915903T ES94915903T ES2172535T3 ES 2172535 T3 ES2172535 T3 ES 2172535T3 ES 94915903 T ES94915903 T ES 94915903T ES 94915903 T ES94915903 T ES 94915903T ES 2172535 T3 ES2172535 T3 ES 2172535T3
Authority
ES
Spain
Prior art keywords
antagonists
endotheline
receptors
endotheline receptors
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915903T
Other languages
English (en)
Spanish (es)
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Catherine Elizabeth Peishoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2172535T3 publication Critical patent/ES2172535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
ES94915903T 1993-04-27 1994-04-26 Antagonistas de los receptores de la endotelina. Expired - Lifetime ES2172535T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
ES2172535T3 true ES2172535T3 (es) 2002-10-01

Family

ID=22071916

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915903T Expired - Lifetime ES2172535T3 (es) 1993-04-27 1994-04-26 Antagonistas de los receptores de la endotelina.

Country Status (28)

Country Link
EP (1) EP0699069B9 (OSRAM)
JP (1) JP3346571B2 (OSRAM)
KR (1) KR100331667B1 (OSRAM)
CN (1) CN1129428C (OSRAM)
AP (1) AP573A (OSRAM)
AT (1) ATE213156T1 (OSRAM)
AU (1) AU682038B2 (OSRAM)
BR (1) BR9406572A (OSRAM)
CA (1) CA2160914A1 (OSRAM)
CZ (1) CZ291189B6 (OSRAM)
DE (1) DE69429861T2 (OSRAM)
DK (1) DK0699069T3 (OSRAM)
DZ (1) DZ1773A1 (OSRAM)
ES (1) ES2172535T3 (OSRAM)
FI (1) FI955103A0 (OSRAM)
HU (2) HUT73763A (OSRAM)
IL (1) IL109443A0 (OSRAM)
MA (1) MA23172A1 (OSRAM)
NO (1) NO313754B1 (OSRAM)
NZ (1) NZ266314A (OSRAM)
PL (1) PL175392B1 (OSRAM)
PT (1) PT699069E (OSRAM)
RU (1) RU2130920C1 (OSRAM)
SG (1) SG49667A1 (OSRAM)
SI (1) SI9400195B (OSRAM)
SK (1) SK130595A3 (OSRAM)
TW (1) TW330204B (OSRAM)
WO (1) WO1994025013A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995035107A1 (en) * 1994-06-20 1995-12-28 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0799225A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
CA2236924A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
SK130098A3 (en) 1996-04-04 1999-05-07 Banyu Pharma Co Ltd Method of treating heart failure with endothelin antagonists
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
CN1234029A (zh) 1996-08-27 1999-11-03 盐野义制药株式会社 色烯-3-羚酸衍生物
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
DE69909273T2 (de) * 1998-04-09 2004-04-22 Merck & Co., Inc. (A New Jersey Corp.) Phosphat-vermittelte cyclisierung
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2005089731A2 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
CN101111472A (zh) 2004-12-21 2008-01-23 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其作为5-ht拮抗剂的用途
WO2006137222A1 (ja) * 2005-06-24 2006-12-28 Tokyo Medical And Dental University 薬剤溶出速度制御方法、及び薬剤溶出性ステント被膜用組成物
EP1909783B1 (en) 2005-08-03 2011-10-12 The Regents of the University of California Illudin analogs useful as anticancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
ES2164054T3 (es) * 1991-11-05 2002-02-16 Smithkline Beecham Corp Antagonistas de receptores de endotelina.

Also Published As

Publication number Publication date
NZ266314A (en) 1998-10-28
CZ291189B6 (cs) 2003-01-15
ATE213156T1 (de) 2002-02-15
DK0699069T3 (da) 2002-05-27
JPH08510211A (ja) 1996-10-29
PL311272A1 (en) 1996-02-05
TW330204B (en) 1998-04-21
NO954291D0 (no) 1995-10-26
NO313754B1 (no) 2002-11-25
IL109443A0 (en) 1994-07-31
EP0699069B1 (en) 2002-02-13
FI955103L (fi) 1995-10-26
MA23172A1 (fr) 1994-12-31
CN1129428C (zh) 2003-12-03
NO954291L (no) 1995-12-21
BR9406572A (pt) 1996-01-30
AP573A (en) 1997-01-30
AU682038B2 (en) 1997-09-18
FI955103A7 (fi) 1995-10-26
CZ283595A3 (en) 1996-03-13
KR100331667B1 (ko) 2002-11-08
AP9400636A0 (en) 1994-04-30
DE69429861T2 (de) 2002-09-19
SI9400195A (en) 1994-12-31
AU6775094A (en) 1994-11-21
EP0699069B9 (en) 2003-10-22
PT699069E (pt) 2002-07-31
EP0699069A1 (en) 1996-03-06
SK130595A3 (en) 1996-06-05
CA2160914A1 (en) 1994-11-10
HUT73763A (en) 1996-09-30
HK1012252A1 (en) 1999-07-30
CN1124923A (zh) 1996-06-19
RU2130920C1 (ru) 1999-05-27
WO1994025013A1 (en) 1994-11-10
FI955103A0 (fi) 1995-10-26
DE69429861D1 (de) 2002-03-21
SI9400195B (sl) 2003-10-31
PL175392B1 (pl) 1998-12-31
HU9503067D0 (en) 1995-12-28
SG49667A1 (en) 1998-06-15
DZ1773A1 (fr) 2002-02-17
HU9501931D0 (en) 1995-09-28
JP3346571B2 (ja) 2002-11-18
EP0699069A4 (OSRAM) 1996-04-03

Similar Documents

Publication Publication Date Title
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
ES2164054T3 (es) Antagonistas de receptores de endotelina.
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
MX9400071A (es) Antagonistas del receptor de endotelina.
ES2139759T3 (es) Antagonistas de citoquina.
ES2083534T3 (es) Nuevos antagonistas de receptores de fibrinogeno.
ES2196534T3 (es) Antagonistas del receptor de vitronectina.
CR6478A (es) Moduladores del receptor glucocorticoide
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
FI941178L (fi) 5-HT4-reseptoriantagonisteja
FI914533A7 (fi) Fibrinogeenireseptoriantagonisteja
GR1001129B (el) Ανταγωνιστες ccκ αναλογου αμινοξεος.
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2190487T3 (es) Nuevos agonistas y antagonistas del receptor de adenosina a1.
MX9101311A (es) Antagonistas receptores de fibrinogeno
DK0804440T3 (da) Tricykliske benzazapin-vasopressionantagonister
FI943941L (fi) CCK-reseptoriantagonisteina käyttökelpoiset bentsodiatsepiinijohdannaiset
EP0539503A4 (OSRAM)
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
MX9300602A (es) Analogos de fenilalanina de bombesina.
ES2195002T3 (es) Antagonistas de los receptores de la endotelina.
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 699069

Country of ref document: ES